Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H9O5.Na |
| Molecular Weight | 280.208 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].OC1=CC=CC=C1C(=O)OC2=CC=CC=C2C([O-])=O
InChI
InChIKey=JOCPDKGMOXSKRO-UHFFFAOYSA-M
InChI=1S/C14H10O5.Na/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17;/h1-8,15H,(H,16,17);/q;+1/p-1
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C14H9O5 |
| Molecular Weight | 257.2183 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23817699 |
https://www.ncbi.nlm.nih.gov/pubmed/6520777
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23817699 |
https://www.ncbi.nlm.nih.gov/pubmed/6520777
Salsalate is a dimer of salicylic acid. Upon administration, it is metabolically hydrolyzed to salicylic acid. Salsalate is is a nonsteroidal anti-inflammatory agent for oral administration for treatment of rheumatoid arthritis, osteoarthritis and related rheumatoid disorders. In addition, salsalate is investigated for treatment of type 2 diabetes.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0001516 Sources: Salsalate selectively inhibits prostaglandin synthesis in vivo |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | DISALCID Approved UseSalsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, and related rheumatic disorder. |
|||
| Palliative | DISALCID Approved UseSalsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder. |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Modulation of endothelial cell activation in sickle cell disease: a pilot study. | 2001 Apr 1 |
|
| Lichenoid drug eruption to salsalate. | 2001 Oct |
|
| Blood pressure elevation in a patient treated with salsalate. | 2002 Apr |
|
| Nonsteroidal antiinflammatory drug starter packs for chronic musculoskeletal pain. | 2002 Jul |
|
| Variable effects of nonsteroidal antiinflammatory agents on thyroid test results. | 2003 Dec |
|
| Interaction of rofecoxib and celecoxib with warfarin. | 2003 Jul 1 |
|
| Aspirin and NSAID sensitivity. | 2004 Aug |
|
| Salicylic acid-induced inactivation of creatine kinase in the presence of lactoperoxidase and H2O2. | 2005 Jan 15 |
|
| Phenolic compounds, sodium salicylate and related compounds, as inhibitors of tumor cell growth and inducers of apoptosis in mouse leukemia L1210 cells. | 2005 Jan-Feb |
|
| Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. | 2006 |
|
| Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy. | 2006 Sep |
|
| siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle. | 2008 Aug |
|
| Salsalate improves glycemia and inflammatory parameters in obese young adults. | 2008 Feb |
|
| Approaches to treatment of pre-diabetes and obesity and promising new approaches to type 2 diabetes. | 2008 Jul |
|
| Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study. | 2008 Mar 12 |
|
| Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. | 2008 May |
|
| Role of NFkappaB in age-related vascular endothelial dysfunction in humans. | 2009 Aug 10 |
|
| Inflammation, insulin resistance, and type 2 diabetes: back to the future? | 2009 Feb |
|
| A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women. | 2009 Jan |
|
| Serum concentration-dependent hepatotoxicity in individuals receiving oral salsalate. | 2009 Jun |
|
| The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. | 2009 Mar |
|
| Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. | 2009 Mar 10 |
|
| Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury. | 2009 Oct |
|
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
| The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. | 2009 Sep |
|
| Apocynin improves insulin resistance through suppressing inflammation in high-fat diet-induced obese mice. | 2010 |
|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
| 2009 World Congress on the Insulin Resistance Syndrome: cardiovascular disease concepts. | 2010 Jul |
|
| Delayed recrudescence to toxic salicylate concentrations after salsalate overdose. | 2010 Jun |
|
| The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects. | 2010 Nov |
|
| An overview of salsalate as a potential antidiabetic therapy. | 2010 Nov |
|
| Wet oxidation of salicylic acid solutions. | 2010 Nov 15 |
|
| Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome. | 2010 Sep |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:11:44 UTC 2023
by
admin
on
Sat Dec 16 11:11:44 UTC 2023
|
| Record UNII |
06SH0H2G8M
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
06SH0H2G8M
Created by
admin on Sat Dec 16 11:11:45 UTC 2023 , Edited by admin on Sat Dec 16 11:11:45 UTC 2023
|
PRIMARY | |||
|
23662396
Created by
admin on Sat Dec 16 11:11:45 UTC 2023 , Edited by admin on Sat Dec 16 11:11:45 UTC 2023
|
PRIMARY | |||
|
DTXSID40178111
Created by
admin on Sat Dec 16 11:11:45 UTC 2023 , Edited by admin on Sat Dec 16 11:11:45 UTC 2023
|
PRIMARY | |||
|
23520-54-9
Created by
admin on Sat Dec 16 11:11:45 UTC 2023 , Edited by admin on Sat Dec 16 11:11:45 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |